American Heart Journal
Volume 141, Issue 1 , Pages 154-155, January 2001

Data and safety monitoring committees: Philosophy and practice:☆☆☆★

Introduction

Durham, NC

Ponte Vedra Beach, Florida October 8-11, 1998

From Duke University, Durham, NC

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Supported by unrestricted educational grants from: Alexion Pharmaceuticals Alkermes, Inc. Astra Hassle AB Astra Merck, Inc. Astra Pharmaceuticals Boehringer Ingelheim (Canada) Ltd Bristol Myers Squibb Centocor, Inc. COR Therapies, Inc. DuPont Merck Genentech, Inc. Healthcare Advisors, Inc. Hoechst Marion Roussel F. Hoffman-La Roche Ltd. Merck Pfizer, Inc. Proliance, Inc. Rhône-Poulenc Rorer Schering-Plough SmithKline Beecham Pharmaceuticals The Medicines Company Vascular Therapies, Inc.

☆☆ Reprint requests: Robert M. Cailiff, MD, Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715.

★ Am Heart J 2001;141:154-5.

PII: S0002-8703(01)20399-8

doi:10.1067/mhj.2001.112500

American Heart Journal
Volume 141, Issue 1 , Pages 154-155, January 2001

Article Tools